Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF). However, no clear survival benefit has been demonstrated, which may in part reflect suboptimal drug expo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Pugliese, Novella, Giordano, Claudia, Nappi, Davide, Luciano, Luigiana, Cerchione, Claudio, Annunziata, Mario, Casale, Beniamino, Crisà, Elena, Villa, Maria Rosaria, Pezzullo, Luca, Iovine, Maria, Picardi, Marco, Grimaldi, Francesco, Pane, Fabrizio, Martinelli, Vincenzo
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6558489/
https://ncbi.nlm.nih.gov/pubmed/30997748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados